Table 2 Safety results for patients in the FAS
Related AE | Arm A—asunercept (n = 26) n (%) | Arm D—atezolizumab (n = 42) n (%) | Arm F—palbociclib (n = 41) n (%) | Arm G—temsirolimus (n = 46) n (%) |
|---|---|---|---|---|
Any AE | 10 (38.5) | 34 (81.0) | 36 (87.8) | 40 (87.0) |
Any SAE | 0 (0) | 9 (21.4) | 6 (14.6) | 10 (21.7) |
Any severe AE (grade 3 or 4) | 0 (0) | 10 (23.8) | 11 (26.8) | 16 (34.8) |
Any DLT/RLT | 0 (0) | 10 (23.8) | 10 (24.3) | 16 (34.8) |
Discontinued study drug due to AE | 0 (0) | 7 (16.7) | 2 (4.9) | 4 (8.7) |
Dose reduction or temporary discontinuation due to AE | 0 (0) | 5 (11.9) | 9 (22.0) | 19 (41.3) |
AE resulting in death | 0 (0) | 0 (0) | 1 (2.4) | 0 (0) |
